GenePeeks and Alliance Global Group Sign Distribution Agreement for Middle East and Africa

Monday, June 19, 2017

CAMBRIDGE, Mass. & DUBAI, United Arab Emirates--(BUSINESS WIRE)-- GenePeeks, Inc., a computational genomics company focused on transforming genetic disease risk analysis, and Alliance Global Group (AGBL) today announced a new partnership to bring GenePeeks’ Virtual Progeny Analytics (VPA) technology platform to select markets in the Middle East and Africa. AGBL is the largest biomedical gateway in these markets.

This collaboration marks another international market for the GenePeeks Preconception Screen, which identifies combined parental risk of passing on more than 1,000 serious genetic diseases. Under the terms of the agreement, AGBL will expand its genetic testing by offering GenePeeks Preconception Screen to patients, healthcare providers and laboratories in the Middle East and Africa. AGBL will also introduce additional applications of GenePeeks’ technology through partnerships with centers of excellence throughout the region.

“We are honored to partner with Alliance Global to address the significant unmet need in these markets for comprehensive preconception screening,” said Anne Morriss, Co-Founder and Chief Executive Officer of GenePeeks. “AGBL’s regional breadth and market knowledge, combined with the analytic power of our advanced computational platform, will give more prospective parents the information and support they need to protect their future families. AGBL is another strong partner for our growing presence outside of the U.S.”

Dr. Tamer Degheidy, Group CEO at Alliance Global stated, “GenePeeks Preconception Screen is an important addition to our growing portfolio of genetic tests, and we’re excited to offer this comprehensive, state-of-the art approach, which reduces the population biases that are associated with traditional carrier screening. It is the first step in our shared mission to transform gene-based clinical applications using GenePeeks’ core technology platform.”

About GenePeeks’ Technology
GenePeeks’ comprehensive approach, called Virtual Progeny Analytics (VPA), uniquely integrates simulated DNA information from two genetic participants to predict the future genome of a child prior to conception. For every mutation in these hypothetical genomes, the company computes a proprietary Variant Gene Dysfunction (VGD) score that predicts gene function and associated disease risk. This next generation approach allows GenePeeks to cover an expanded number of diseases with increased sensitivity and evaluate variants that may remain uncharacterized by other genetic tests, while avoiding the confusion and anxiety that can be associated with carrier testing. In contrast to carrier screening, which identifies parental carrier status, GenePeeks focuses on a future child’s true risk of disease inheritance. GenePeeks offers this physician-ordered service through its CLIA certified clinical laboratory.

About GenePeeks
GenePeeks is a computational genomics company focused on identifying inherited disease risk in future generations. GenePeeks’ patented technology digitally combines the genetic information of two potential parents, simulating the complex genetic interactions that occur naturally in human reproduction. The company’s proprietary platform creates and analyzes thousands of Virtual Progeny to uncover disease risk that cannot be seen with alternative screening tools. GenePeeks offers this physician-ordered service through its CLIA certified clinical laboratory. GenePeeks is privately held, with corporate offices in Cambridge, Mass. For more information, visit www.genepeeks.com

GenePeeks’ next-generation screening technology is available today. For more information about becoming a partner, please contact support@genepeeks.com

About Alliance Global Group (AGBL)
The AGBL Group of companies is the largest biomedical gateway to the emerging markets of the Middle East, Africa and Asia. The group is dedicated to bringing innovative technologies and products to researchers, clinicians, and diagnostic users in the emerging healthcare markets within the MENA region. The group employs dedicated teams of product and applications specialists, and has many offices across the region offering distribution, consulting and product development services to world-renowned manufacturers of biomedical technologies. The group’s stated mission is to improve the lives of the region’s inhabitants through novel biomedical technologies and products. For more information, please visit: www.agbl.net

TOP